SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 19, 2001
Hologic, Inc.
-------------------------------------------------------------------------------
(Exact Name Of Registrant As Specified In Its Charter)
Delaware
-------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-18281 04-2902449
---------------------------------- ------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
35 Crosby Drive 01730
-------------------------------------------- ------------------
(Address of Principal Executive Offices) (Zip Code)
(781) 999-7300
-------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N/A
-------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
------
As we previously announced, on December 14, 2001, we commenced a public
offering of 3,000,000 shares of our Common Stock, at a price of $9.00 per share,
including 390,000 shares to cover the underwriters' over-allotments. Needham &
Company, Inc. and Stephens Inc. were the underwriters for the offering. The
underwriters exercised their over-allotment option, and purchased all 3,000,000
shares. The closing of our sale of 2,610,000 shares took place on December 19,
2001, and the closing of our sale of the 390,000 shares to cover over-allotments
took place on December 21, 2001. The offering completes the sale of all shares
of stock covered by our shelf registration statement on Form S-3, initially
filed with the Securities and Exchange Commission on November 16, 2001. We plan
to use the net proceeds of the offering to fund the continued development of our
DirectRay direct-to-digital mammography system, including conducting clinical
trials and working toward regulatory approvals, as well as to fund research and
development and for general corporate purposes and working capital.
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: January 3, 2002 Hologic, Inc.
By: /s/ Glenn P. Muir
-----------------
Glenn P. Muir, Chief Financial Officer